Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease

Abstract

Background-Recent studies have shown that type 2 diabetes is preventable by both lifestyle interventions and medications that influence primary glucose metabolism. Whether pharmacological interventions that influence primary lipid metabolism can also delay development of type 2 diabetes is unknown. The goal of this study was to evaluate the effect of the peroxisome proliferator-activated receptor ligand bezafibrate on the progression of impaired fasting glucose phase to type 2 diabetes in patients with coronary artery disease over a 6.2-year follow-up period. Methods and Results-The study sample comprised 303 nondiabetic patients 42 to 74 years of age with a fasting blood glucose level of 110 to 125 mg/dL (6.1 to 6.9 mmol/L).

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

“…PPAR-γ is another target of bezafibrate and is expected to have effects on glucose metabolism and insulin resistance [36]. Several previous studies have indicated that bezafibrate treatment could be associated with improvement of glycemic control in diabetic subjects [37,38] or with delay of the onset of T2DM [39,40]. As for fenofibrate treatment, on the other hand, there are conflicting reports on its effect on glycemic control [41,42].…”

Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes

“…Recent in vitro experiments have shown that bezafibrate serves as a pan-agonist for PPAR␣, -␥, and -␦ (9,48). Furthermore, recent extended clinical trials (15,43) have highlighted its antidiabetic properties. However, the underlying mechanism is not fully clarified.…”

The role of PPAR in myocardial response to ischemia in normal and diseased heart

“…Several synthetic agonists of PPAR-α and PPAR-γ are known as marketed drugs used in the treatment of hypertrigliceridemia and diabetes mellitus, respectively (Ballantyne et al 2003;Tenenbaum et al 2004). Hypolipidemic drugs fibrates (e.g.…”